文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

实体瘤患者ICU住院后恢复癌症治疗的相关因素

Factors associated with cancer treatment resumption after ICU stay in patients with solid tumors.
PubMed 文献 · Ann Intensive Care · 2024-08-31
一句话结论实体瘤患者ICU后体能状态下降(ΔPS)独立与无法恢复癌症治疗(OR 0.34)及1年死亡(HR 1.76)相关。

该回顾性研究纳入2014至2019年法国一所大学附属医院ICU收治的219例实体瘤患者,中位SAPS II为44.0。ICU存活出院的136例中,81例(59.6%)在ICU出院后接受了癌症治疗。ICU后体能状态(PS)3或4分者从入ICU时的16.2%升至存活者的44.5%,PS中位下降1.5分(95%CI -1.5至-1.0,p<0.001)。ΔPS独立与无法接受癌症治疗(OR 0.34,95%CI 0.18-0.56,p<0.001)及ICU出院存活者1年死亡(HR 1.76,95%CI 1.34-2.31,p<0.001)相关。作者认为改善患者一般状况的多学科干预可能改善癌症治疗可及性和长期生存。

要点

  • ICU存活出院的136例实体瘤患者中仅81例(59.6%)在ICU出院后接受了癌症治疗。
  • ICU后PS 3或4分者从入ICU时16.2%升至存活者的44.5%,PS中位下降1.5分(95%CI -1.5至-1.0,p<0.001)。
  • ΔPS独立与无法接受癌症治疗相关(OR 0.34,95%CI 0.18-0.56,p<0.001)。
  • ΔPS独立与ICU出院存活者1年死亡相关(HR 1.76,95%CI 1.34-2.31,p<0.001)。
  • ICU前PS(OR 3.73,95%CI 2.01-7.82,p<0.001)和ICU住院时长(OR 1.23,95%CI 1.06-1.49,p=0.018)独立与ICU后PS差相关。

适用人群与场景

  • 2014至2019年法国一所大学附属医院ICU收治的全部实体瘤患者(回顾性研究),共219例。

研究设计与关键结果

  • 研究类型:回顾性研究;样本量219例;单中心(法国一所大学附属医院);人群为实体瘤ICU患者;中位SAPS II 44.0(IQR 32.8-66.3)。
  • ICU存活出院136例(62.3%),其中81例(59.6%)在ICU出院后接受癌症治疗。
  • ICU后PS 3或4分者:入ICU时16.2% vs ICU存活者44.5%;PS中位下降1.5分(95%CI -1.5至-1.0,p<0.001)。
  • ΔPS独立与无法接受癌症治疗相关:OR 0.34(95%CI 0.18-0.56,p<0.001)。
  • ΔPS独立与ICU出院存活者1年死亡相关:HR 1.76(95%CI 1.34-2.31,p<0.001)。
  • ICU前PS(OR 3.73,95%CI 2.01-7.82,p<0.001)和ICU住院时长(OR 1.23,95%CI 1.06-1.49,p=0.018)独立与ICU后PS差相关。
  • 生存率:ICU出院时62.3%(n=136),1年27.3%(n=59),3年17.1%(n=37)。
  • ICU后恢复癌症治疗者中位生存771天(95%CI 376-1058),未恢复者29天(95%CI 15-49),p<0.001。

证据类型、等级与局限

  • 证据类型:回顾性研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,在ICU期间及ICU后通过多学科干预改善患者一般状况,可能改善其获得癌症治疗的机会和长期生存。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Post-intensive care syndrome could be responsible for inability to receive proper cancer treatment after ICU stay in patients with solid tumors (ST). Our purpose was to determine the factors associated with cancer treatment resumption and the impact of cancer treatment on the outcome of patients with ST after ICU stay.

METHODS: We conducted a retrospective study including all patients with ST admitted to the ICU between 2014 and 2019 in a French University-affiliated Hospital.

RESULTS: A total of 219 patients were included. Median SAPS II at ICU admission was 44.0 [IQR 32.8, 66.3]. Among the 136 patients who survived the ICU stay, 81 (59.6%) received cancer treatment after ICU discharge. There was an important increase in patients with poor performance status (PS) of 3 or 4 after ICU stay (16.2% at admission vs. 44.5% of patients who survived), with significant PS decline following the ICU stay (median difference - 1.5, 95% confidence interval [-1.5-1.0], p < 0.001). The difference between the PS after and before ICU stay (delta PS) was independently associated with inability to receive cancer treatment (Odds ratio OR 0.34, 95%CI 0.18-0.56, p value < 0.001) and with 1-year mortality in patients who survived at ICU discharge (Hazard ratio HR 1.76, 95%CI 1.34-2.31, p value < 0.001). PS before ICU stay (OR 3.73, 95%IC 2.01-7.82, p value < 0.001) and length of stay (OR 1.23, 95%CI 1.06-1.49, p value 0.018) were independently associated with poor PS after ICU stay. Survival rates at ICU discharge, at 1 and 3 years were 62.3% (n = 136), 27.3% (n = 59) and 17.1% (n = 37), respectively. The median survival for patients who resumed cancer treatment after ICU stay was 771 days (95%CI 376-1058), compared to 29 days (95%CI 15-49) for those who did not resume treatment (p < 0.001).

CONCLUSION: Delta PS, before and after ICU stay, stands out as a critical determinant of cancer treatment resumption and survival after ICU stay. Multidisciplinary intervention to improve the general condition of these patients, in ICU and after ICU stay, may improve access to cancer treatment and long-term survival.

来源:Ann Intensive Care,查看原文。版权归原作者所有。

参考来源

  1. Benguerfi S, Messéant O, Painvin B, et al. Factors associated with cancer treatment resumption after ICU stay in patients with solid tumors. Ann Intensive Care. 2024. PMID: 39215851. doi:10.1186/s13613-024-01366-3

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。